This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	MicroRNA-10b (miR-10b)	<p><i>In vitro</i> and mouse studies suggest that antagonizing miR-10b could help prevent breast cancer metastasis. In mice, an anti-miRNA oligonucleotide (antagomir) against miR-10b significantly decreased breast cancer metastases to the lung compared with vehicle ($p < 1 \times 10^{-4}$). Planned work includes studies in other animal models of cancer.</p> <p>Regulus Therapeutics Inc. has antagomirs and other miRNA-targeting compounds in preclinical development to treat cancer, metabolic disease, HCV infection and other indications.</p> <p>Rosetta Genomics Ltd.'s ASO-MOE-191, a chemically modified antisense oligonucleotide targeting miR-191, is in preclinical testing to treat liver cancer.</p> <p>SciBX 3(13); doi:10.1038/scibx.2010.401 Published online April 1, 2010</p>	Patented by Regulus Therapeutics; licensing status undisclosed	<p>Ma, L. <i>et al. Nat. Biotechnol.</i>; published online March 28, 2010; doi:10.1038/nbt.1618</p> <p>Contact: Robert A. Weinberg, Massachusetts Institute of Technology, Cambridge, Mass. e-mail: weinberg@wi.mit.edu</p>